date:Feb 09, 2022
2022[1], the randomized, double-blind, sustained, crossover-controlled intervention was conducted at the Sant Joan de Reus University Hospital in Barcelona. The study was led by Dr. Rosa Valls, and included 67 adult hypercholesterolemic volunteers with relatively high blood LDL levels.
Each participant consumed 250mg ABG+ or a placebo over six weeks, with a three-week washout period before crossover. Subjects also were assigned a set diet that excluded lipo-lowering and anti-hypertensive foods